NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · AKTS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aktis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aktis Oncology, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aktis Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2024 | -$0.14-16.67% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Feb 13, 2024 | -$0.19-5.56% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 13, 2023 | -$0.26-44.44% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $37.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
$31.27-$1.34 (-4.11%)
Immunocore Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 23.2% below the high.
$6.30-$0.11 (-1.64%)
Aura Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.01% below the high.
$3.82-$0.06 (-1.55%)
Bicycle Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$8.00-$1.20 (-13.04%)
Akari Therapeutics, Plc’s quoted price sits in the lower half of its reported 52-week range, 76.19% below the high.
